Melanotan I vs Melanotan II: A Research Comparison

Melanotan I and Melanotan II are usually discussed together because they share an origin: both are synthetic analogues of α-melanocyte-stimulating hormone (α-MSH) developed at the University of Arizona in the 1980s as tools for studying pigmentation and for inducing melanin without ultraviolet exposure. Despite the near-identical names, they are structurally and pharmacologically distinct, with very different development paths. One became an approved orphan drug; the other remains an unapproved research compound widely sold outside regulatory oversight.

People searching for this comparison usually want to understand why two α-MSH derivatives that both darken skin are treated so differently by regulators, and how their receptor selectivity translates into different research profiles.

Research-only notice. The information below is provided for educational and scientific reference. Melanotan II is not approved for human use in any jurisdiction; Melanotan I (afamelanotide) is an approved prescription drug only for a specific rare indication. Nothing here is medical advice, a dosing recommendation, or an endorsement of use. These compounds are discussed as research subjects.

Mechanism and receptor selectivity

Melanotan I is the compound originally described as NDP-α-MSH, or [Nle4, D-Phe7]-α-MSH. It retains the full 13-residue backbone of native α-MSH but carries two substitutions — norleucine at position 4 and D-phenylalanine at position 7 — that block enzymatic degradation and confer what the original 1980 report called “ultralong biological activity” relative to the rapidly cleared natural hormone. It behaves as a melanocortin receptor agonist with a relative preference for the melanocortin-1 receptor (MC1R) on epidermal melanocytes, where activation shifts pigment production toward eumelanin, the darker, more photoprotective pigment. This comparatively focused action on cutaneous MC1R signalling is central to its therapeutic rationale.

Melanotan II took a different chemical strategy. It is a truncated, cyclic lactam analogue (Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-NH2) engineered for superpotency and metabolic stability by constraining the peptide into its active conformation. The trade-off is selectivity: Melanotan II is a broadly non-selective agonist across the melanocortin receptor family (MC1R through MC5R). Its activity at MC4R in the central nervous system is associated with effects on sexual arousal and appetite, and MC3R/MC4R activity is linked to nausea via the brainstem. In short, Melanotan I produces a relatively narrow pigmentary effect, while Melanotan II produces pigmentation plus a range of systemic melanocortin effects that its designers exploited but that also broaden its adverse-effect profile.

Evidence and development status

The two compounds diverge most sharply in how far their evidence has been developed. Melanotan I was carried through formal clinical development as afamelanotide and delivered as a bioresorbable subcutaneous implant that releases the peptide over roughly two months. A pivotal randomized controlled trial published in the New England Journal of Medicine in 2015 found that patients with erythropoietic protoporphyria (EPP), a rare disorder causing severe phototoxic pain, accumulated significantly more pain-free time in direct sunlight on afamelanotide than on placebo. That evidence base supported EMA approval in 2014 and FDA approval in October 2019. Afamelanotide has also been explored as a research subject in vitiligo and polymorphous light eruption.

Melanotan II never completed that journey. It was evaluated in early pilot work — a phase-I tanning study by Dorr and colleagues in 1996 and a small placebo-controlled erectile-function study by Wessells and colleagues in 1998 — but development stalled, partly because pronounced nausea and slow onset limited tolerability. Interest instead shifted to a Melanotan II metabolite, bremelanotide (PT-141), pursued separately for sexual-function indications. Melanotan II itself has no completed large-scale efficacy trials and no marketing approval, and much of its human documentation now comes from adverse-event and case-report literature.

Research and safety context

Because Melanotan II is sold online as an injectable “tanning” or libido product, it has generated a distinctive safety literature. Published case reports describe systemic sympathomimetic toxicity and rhabdomyolysis after overdosing, priapism, posterior reversible encephalopathy, and dermatological complications. A 2017 review in the International Journal of Dermatology catalogued concerns around unregulated use of α-MSH analogues, including change in existing moles, new dysplastic nevi, and case reports of melanoma emerging during or after use. These reports do not establish causation but underline why melanocortin agonists that darken nevi are viewed cautiously.

Melanotan I is not exempt from those pigmentary concerns — any MC1R agonist can darken moles. The key difference is that afamelanotide is used within a monitored clinical framework at a defined dose and indication, whereas Melanotan II is typically self-sourced without oversight or standardized purity.

Key differences

• Structure: Melanotan I is a linear, full-length 13-residue α-MSH analogue; Melanotan II is a shorter cyclic lactam.
• Selectivity: Melanotan I is relatively MC1R-preferring; Melanotan II is non-selective across MC1R–MC5R, with added MC3R/MC4R (sexual-function, appetite, nausea) effects.
• Regulatory standing: Melanotan I is an approved drug (afamelanotide) for a rare disease; Melanotan II is unapproved everywhere.
• Evidence quality: Melanotan I has randomized controlled-trial support; Melanotan II rests on small early studies plus harm case reports.
• Delivery: Afamelanotide is a slow-release implant given every two months; Melanotan II is short-acting and injected repeatedly in unregulated use.

Which for what research?

Framed strictly as research subjects, the two answer different questions. Melanotan I / afamelanotide is the reference compound for investigating targeted MC1R-driven photoprotection and pigmentation biology, and it is the only one of the pair with a regulated clinical role and controlled-trial data behind it. Melanotan II is of interest to researchers studying the broader melanocortin system — how non-selective agonism simultaneously touches pigmentation, MC4R-mediated sexual signalling, and appetite — while also serving as a case study in the risks of unregulated peptide use. Neither profile constitutes guidance for personal use; the appropriate choice depends on the receptor pharmacology under examination and the applicable ethical and legal framework.

Put these side by side in the Compare Peptides tool.

Sources

• Sawyer TK, et al. 4-Norleucine, 7-D-phenylalanine-α-melanocyte-stimulating hormone: a highly potent α-melanotropin with ultralong biological activity. Proc Natl Acad Sci USA. 1980. PMID 6777774
• Al-Obeidi F, et al. Potent and prolonged acting cyclic lactam analogues of α-melanotropin: design based on molecular dynamics. J Med Chem. 1989. PMID 2555512
• Dorr RT, et al. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sci. 1996. PMID 8637402
• Wessells H, et al. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. J Urol. 1998. PMID 9679884
• Langendonk JG, et al. Afamelanotide for erythropoietic protoporphyria. N Engl J Med. 2015. PMID 26132941
• Nelson ME, Bryant SM, Aks SE. Melanotan II injection resulting in systemic toxicity and rhabdomyolysis. Clin Toxicol (Phila). 2012. PMID 23121206
• Habbema L, et al. Risks of unregulated use of α-melanocyte-stimulating hormone analogues: a review. Int J Dermatol. 2017. PMID 28266027